We are grateful to our Silver sponsors for committing £ 5,000 towards this world Congress. The sponsorship monies will enable EB 2020 to be a truly ground-breaking industry event and to have longevity beyond the four days of Congress.
We look forward to working with our sponsors.
To find out more about becoming a sponsor please visit our sponsorship opportunities page to see the benefits of sponsoring EB 2020 for your company. Jenny Jackson, Sponsorship Lead would be delighted to talk about tailoring the packages for your company’s needs, please contact Jenny via email@example.com to discuss ways your company can get involved.
InMed is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is our bioinformatics platform, which uses a computer-based drug candidate selection process to reach high-probability conclusions from massive, publicly available databases together with an internal library of cannabinoid drug information.
InMed is also developing a robust, high-yield, microbial-based biosynthesis process designed to enable the manufacturing of the multitude of cannabinoids (90+) found from natural sources. InMed’s products are designed to be bio-identical to the naturally-occurring cannabinoids and the process envisioned to offer cost and time savings, and superior ease, control and quality of manufacturing when compared to alternative methods.
RHEACELL GmbH & Co. KG
RHEACELL GmbH & Co. KG (RHEACELL), the subsidiary of TICEBA, is dedicated to the development of pharmaceuticals based on ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) as a platform technology. TICEBA produces stem cells of the highest quality as pharmaceuticals (§13 AMG) for its subsidiary for currently seven phase I/IIa clinical trials.
As part of the development process of stem cell-based pharmaceuticals RHEACELL makes use of several patents hold by Harvard University/Cambridge that are worldwide exclusively licensed to RHEACELL. Markus Frank, M. D., Professor of Pediatrics and Dermatology at Harvard Medical School, is assisting RHEACELL as scientific advisor. He has particular expertise in stem cell research.
RHEACELL is recruiting patients with recessive dystrophic epidermolysis bullosa (RDEB) for an international FDA approved phase I/IIa multicenter clinical trial with allogeneic ABCB5+ MSCs. The MSC product of RHEACELL has been granted Orphan Drug Designation for the treatment of RDEB in the EU and USA.
Constant Therapeutics is a clinical stage company developing proprietary compounds that stimulate the Alternative Renin Angiotensin System for treatment of CNS and rare disorders. It’s lead clinical programs are in stroke recovery, epidermolysis bullosa (EB) and cardiomyopathy associated with Duchenne Muscular Dystrophy. The Company’s compound, TXA127, a pharmaceutical formulation of the naturally occurring Mas receptor ligand peptide angiotensin-(1-7), has demonstrated excellent results in the C7 hypomorphic mouse model of RDEB by reducing the progression of mutilating deformities and dermal fibrosis. TXA127 works in EB by down-modulating inflammation and the fibrotic activity of the TGF-beta pathway. Constant is currently developing an oral formulation of TXA127, which we plan to use in the Phase II clinical trial.